PA
VRTX icon

Procyon Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Procyon Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Sell
2,924
-285
-9% -$126K 0.06% 234
2026
Q1 		$1.43M Buy
3,209
+3
+0.1% +$1.4K 0.07% 228
2025
Q4 		$1.45M Sell
3,206
-139
-4% -$59.9K 0.07% 221
2025
Q3 		$1.31M Sell
3,345
-1,083
-24% -$453K 0.08% 203
2025
Q2 		$1.97M Sell
4,428
-14,170
-76% -$6.53M 0.18% 107
2025
Q1 		$9.02M Buy
18,598
+3,963
+27% +$1.85M 0.55% 42
2024
Q4 		$5.89M Sell
14,635
-375
-2% -$174K 0.37% 57
2024
Q3 		$6.98M Buy
15,010
+157
+1% +$75.4K 0.48% 47
2024
Q2 		$6.96M Buy
14,853
+530
+4% +$230K 0.52% 48
2024
Q1 		$5.99M Buy
14,323
+636
+5% +$269K 0.46% 52
2023
Q4 		$5.57M Buy
13,687
+939
+7% +$347K 0.47% 45
2023
Q3 		$4.43M Buy
12,748
+5,375
+73% +$1.88M 0.45% 51
2023
Q2 		$2.59M Buy
7,373
+4,028
+120% +$1.36M 0.33% 72
2023
Q1 		$1.05M Buy
3,345
+643
+24% +$193K 0.18% 127
2022
Q4 		$780K Buy
2,702
+1,424
+111% +$434K 0.14% 148
2022
Q3 		$370K Sell
1,278
-88
-6% -$25.3K 0.09% 205
2022
Q2 		$385K Buy
1,366
+37
+3% +$9.9K 0.08% 218
2022
Q1 		$347K Buy
+1,329
New +$315K 0.07% 236
2020
Q3 		– Sell
-272
Closed -$79K – 1031
2020
Q2 		$79K Hold
272
– – 0.04% 322
2020
Q1 		$65K Hold
272
– – 0.04% 301
2019
Q4 		$60K Buy
+272
New +$55K 0.04% 327

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Procyon Advisors's VRTX Position: Q2 2026 in Review

Procyon Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 8.9% in Q2 2026, selling an estimated $126K and leaving 2,924 shares worth $1.45M. The position accounts for 0.06% of the portfolio, ranked #234.

Procyon Advisors first reported a position in VRTX in Q4 2019 and has held it in 21 quarters since. The position peaked at $9.02M in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Procyon Advisors held 2,924 shares of Vertex Pharmaceuticals worth $1.45M as of Q2 2026.
  • Procyon Advisors sold 285 Vertex Pharmaceuticals shares in Q2 2026, an estimated $126K.
  • Vertex Pharmaceuticals made up 0.06% of Procyon Advisors's portfolio in Q2 2026, its #234 holding.
  • Procyon Advisors first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 21 quarters since.
  • Procyon Advisors's Vertex Pharmaceuticals position peaked at $9.02M in Q1 2025.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Procyon Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.